12/16/2020

Aachen, Germany, 16 December 2020 Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain.

12/1/2020

Aachen, Germany, 1 December 2020 Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights (excluding Spain and the UK) to CRESTOR™ (rosuvastatin) and its associated brands for a total consideration of up to US$ 350 million. CRESTOR™ is among the leading statin products in Europe and is indicated for the treatment of dyslipidaemia, hypercholesterolaemia and the prevention of cardiovascular events. Compared to other statins such as atorvastatin, CRESTOR™ has demonstrated superior LDL- cholesterol- lowering efficacy¹. The level of LDL is an important factor for the improvement of cardiovascular outcomes and therefore especially important in patients with high risk of cardiovascular diseases such as diabetes or stroke.

7/21/2020

Aachen, Germany & Morristown, N.J. – 21 July 2020 – Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.² QUTENZA® is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin.

6/16/2020

Aachen, Deutschland, 16. Juni 2020 – Grünenthal, ein weltweit führendes Unternehmen im Bereich der Schmerzbehandlung und verwandten Erkrankungen, durfte sich am 15. Juni 2020 über eine besondere Auszeichnung freuen: Bereits zum vierten Mal wurde das Aachener Unternehmen mit dem renommierten Zertifikat zum audit berufundfamilie ausgezeichnet – diesmal jedoch sogar mit dem Zusatz „mit dauerhaftem Charakter“. Damit wird das Zertifikat, das als Qualitätssiegel für eine strategisch angelegte familien- und lebensphasenbewusste Personalpolitik gilt, nicht mehr nur für einen bestimmten Zeitraum, sondern dauerhaft vergeben. Zu den Gratulant*innen zählte unter anderem Bundesfamilienministerin Dr. Franziska Giffey, die die Schirmherrschaft übernommen hat.

2/4/2020

Aachen, Germany, 04 February 2020 – Grünenthal, a global leader in pain management and related diseases, has announced it will now include electric and hybrid engines in the fleet of company cars for managers at its site in Aachen, Germany. The decision is part of the company’s ongoing commitment to promoting sustainability by reducing the environmental footprint of its operations. And it also marks the latest step forward in its long tradition of investing in future-facing technologies.

1/29/2020

Aachen, Germany and Boston, USA / 29 January 2020 — Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with leading scientists and institutions.